Moderna
MRNA
1,006 hedge funds and large institutions have $42.8B invested in Moderna in 2022 Q1 according to their latest regulatory filings, with 132 funds opening new positions, 403 increasing their positions, 327 reducing their positions, and 220 closing their positions.
23% more repeat investments, than reductions
Existing positions increased: 403 | Existing positions reduced: 327
5% more funds holding in top 10
Funds holding in top 10: 22 → 23 (+1)
0.91% more ownership
Funds ownership: 60.81% → 61.71% (+0.91%)
6% less call options, than puts
Call options by funds: $3.32B | Put options by funds: $3.54B
9% less funds holding
Funds holding: 1,109 → 1,006 (-103)
31% less capital invested
Capital invested by funds: $62.5B → $42.8B (-$19.7B)
40% less first-time investments, than exits
New positions opened: 132 | Existing positions closed: 220
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Coatue Management
New York
|
+$445M |
| 2 |
Renaissance Technologies
New York
|
+$334M |
| 3 |
TP
Theleme Partners
London,
United Kingdom
|
+$221M |
| 4 |
BlackRock
New York
|
+$170M |
| 5 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$147M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Barclays
London,
United Kingdom
|
-$335M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$329M |
| 3 |
Morgan Stanley
New York
|
-$325M |
| 4 |
Allianz Asset Management
Munich,
Germany
|
-$120M |
| 5 |
Jane Street
New York
|
-$117M |
MRNA Hedge Fund Activity: Q1 2022 in Review
1,006 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Moderna (MRNA) for Q1 2022, worth a combined $42.8B — down 31% from $62.5B a quarter earlier.
Sellers outnumbered buyers: 220 funds closed out of MRNA and 132 opened new positions — a net loss of 88 holders — while 327 trimmed existing stakes and 403 added.
The largest buyer was Coatue Management, adding an estimated $445M. The largest seller was Barclays, cutting an estimated $335M.
- 1,006 institutional investors held Moderna (MRNA) as of Q1 2022, down from 1,109 in Q4 2021.
- Funds reported $42.8B of Moderna stock for Q1 2022, down 31% quarter-over-quarter.
- 132 funds opened new Moderna positions in Q1 2022 and 220 closed out, a net change of -88 holders.
- The largest Moderna buyer in Q1 2022 was Coatue Management, an estimated $445M added.
- The largest Moderna seller in Q1 2022 was Barclays, an estimated $335M sold.
Based on aggregated 13F filings for Q1 2022.